Etanercept as monotherapy in patients with psoriasis.

By C. Leonardi, J. Powers, R. Matheson, B. Goffe, R. Zitnik, Andrea Wang, A. Gottlieb. New England Journal of Medicine, 2003

1,201 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. (2012, neutral): “Nasopharyngitis 5 (19) 3 (11) 3 (10) 3 (10) 4 (14)”
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis (2006, background): “This observation is consistent with the effi cacy of anti-TNF–directed therapies in psoriasis (27, 28).”
Treatment recommendations for psoriatic arthritis (2008, background): “28 The efficacy of therapies for psoriatic nail disease is not well studied; see table 2 for existing evidence.”
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “In addition, although etanercept has efficacy comparable to infliximab and adalimumab in RA, etanercept may be less efficacious than infliximab or adalimumab in psoriasis (Leonardi et al., 2003; Gottlieb et al., 2004; Gordon et al., 2006).”